Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official...

Sangri Today
Sangri Today Verified Media or Organization • 11 Apr, 2026 Super Admin
June 1, 2022 • 11:12 AM  0
S
Sangri Today Spotlight
BREAKING
Sangri Today
Sangri Today
4 years ago
Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial
uRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial
TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official...
Full Story: https://www.sangritoday.com/spotlight/dundee-corporation-portfolio-holding-taurx-pharmaceuticals-ltd-announces-move-toward-regulatory-submission-following-initial-data-from-lucidity-trial
https://www.sangritoday.com/spotlight/dundee-corporation-portfolio-holding-taurx-pharmaceuticals-ltd-announces-move-toward-regulatory-submission-following-initial-data-from-lucidity-trial
Google News
Copied
Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official announcement, please visit:

history This is an archived post. The information provided may be outdated.

Sangri Today Verified Media or Organization • 11 Apr, 2026 Super Admin

Sangri Today is a news website of news and current affairs that publishes news reports from various places, from general reports.

home Home amp_stories Web Stories local_fire_department Trending play_circle Videos mark_email_unread Newsletter